U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Guidance for Industry November 2004

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2005-D-0273
Issued by:
Guidance Issuing Office
Center for Biologics Evaluation and Research

This guidance provides to you, medical device manufacturers of communicable disease tests, information about performing studies to support modifying the indication for use to include testing of cadaveric blood pecimens to screen donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). This guidance makes recommendations about: 

• Sensitivity and specificity studies • Reproducibility studies • Number of test kit lots to include in studies
• Plasma dilution issues
• Information about specimen collection times to be included


This document contains information which has been provided in Center for Biologic Evaluation and Research’s (CBER’s) letters to manufacturers of communicable disease tests. We, FDA, continue to encourage Manufacturers of communicable disease tests to evaluate these tests for cadaveric HCT/P donor use and seek such labeling.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2005-D-0273.

Questions?

Contact Point
Office of Communication, Outreach and Development (OCOD)
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3128
Silver Spring, MD 20993-0002
ocod@fda.hhs.gov
(800) 835-4709
(240) 402-8010
Back to Top